Version 1
: Received: 22 July 2024 / Approved: 23 July 2024 / Online: 24 July 2024 (07:03:22 CEST)
Version 2
: Received: 19 August 2024 / Approved: 20 August 2024 / Online: 20 August 2024 (12:36:45 CEST)
How to cite:
Odent, J.; Baleine, N.; Torcasio, S. M.; Gautier, S.; Coulembier, O.; Raquez, J.-M. 3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release. Preprints2024, 2024071819. https://doi.org/10.20944/preprints202407.1819.v2
Odent, J.; Baleine, N.; Torcasio, S. M.; Gautier, S.; Coulembier, O.; Raquez, J.-M. 3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release. Preprints 2024, 2024071819. https://doi.org/10.20944/preprints202407.1819.v2
Odent, J.; Baleine, N.; Torcasio, S. M.; Gautier, S.; Coulembier, O.; Raquez, J.-M. 3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release. Preprints2024, 2024071819. https://doi.org/10.20944/preprints202407.1819.v2
APA Style
Odent, J., Baleine, N., Torcasio, S. M., Gautier, S., Coulembier, O., & Raquez, J. M. (2024). 3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release. Preprints. https://doi.org/10.20944/preprints202407.1819.v2
Chicago/Turabian Style
Odent, J., Olivier Coulembier and Jean-Marie Raquez. 2024 "3D-Printed Phenylboronic Acid-Bearing Hydrogels for Glucose-Triggered Drug Release" Preprints. https://doi.org/10.20944/preprints202407.1819.v2
Abstract
Diabetes is a major health concern that the next-generation of on-demand insulin releasing implants may overcome for personalized therapy. Therein, 3D-printed phenylboronic acid-containing subcutaneous implants with on-demand glucose-triggered drug release abilities are produced using high resolution stereolithography technology. To that end, the methacrylation of phenylboronic acid is targeted following a two-step reaction. The resulting photocurable phenylboronic acid derivative is accordingly incorporated within bioinert polyhydroxyethyl methacrylate-based hydrogels at varying loadings. The end result are sub-centimeter scaled 3D-printed bionert implants that can be remotely activated with 1,2-diols and 1,3-diols such as glucose for on-demand drug administration such as insulin. As a proof of concept, varying glucose concentration from hypoglycemia to hyperglycemia levels readily allow the release of pinacol, i.e. a model molecule with similar release properties than insulin, at respectively low and high rates. In addition, the results demonstrated that adjusting the geometry and size of the 3D-printed part is a simple and suitable method for tailoring the release behavior and dosage.
Keywords
3D printing; drug eluting implants; glucose responsiveness
Subject
Chemistry and Materials Science, Materials Science and Technology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.